- Dare Bioscience press release ( NASDAQ: DARE ): Q2 GAAP EPS of $0.00.
- Revenue of $10M.
- License fee revenue recognition: $10.0 million during 2Q-2022 in connection with the closing under the global license agreement with Organon to commercialize XACIATO
- Upon the first commercial sale of XACIATO, currently expected in 4Q-2022, we may receive another $2.5 million in license fee revenue.
- Cash and cash equivalents: $32.1 million at June 30, 2022, compared to $51.7 million at December 31, 2021.
For further details see:
Dare Bioscience GAAP EPS of $0.00, revenue of $10M